INO
XBI Potential What is XBi?
XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap as we see it. This highly efficient fund, which charges less than competing funds, has a history of beating its index due to revenue from securities lending. It has attracted a large asset base and trades with excellent volume. The fund’s alternative take on the space earns it a place on our Opportunities List.
Looking like we could see a pull back here or breakout.
Risk and reward is in our favor here. if it rejects, it can go to $95 area, if it breaks out, we can just stoploss for $1.
INO Trend line reversal and break outINO is looking to hold a $10 trend line for its bounce and reversal back to the upside after being downgraded last week.
Watch for breakout RED or GREEN.
Not too late to buy INO(maybe MOON)Possible pull back reasons:
BTC halving: Millenials are into crypto and a lot of people made money June last year before the LTC halving. People are hyped because this is the last major halving for 4 years. And might be selling their stocks or fresh INO gains to get into BTC. PLUS miners usually plan ahead for the bitcoin halvings and buy extra equipment to not suffer any major losses. BUt CORORNAviruis might have put a stop to the equipment the miners need to keep BTC mining profitable. If that is true then we might see something close to 2017. But I expect miner had their equipment before this all happened. Or will get it in the month before the next halving.
People forget: America moves fast. if something major happens on Monday it's lucky to be stilled talked about the next Monday. So people are naturally not talking about the coronaviruis and people might care less and less about the vaccine by the time it is ready to be sold. We are aslo seeing states open stores and businesses more and more. That will distract from a vaccine as well.
Overall, INO is into more than just a COVID19 vaccine. And I think, after some interview I've seen recently, Mad money, the CEO and the company is run with good intention and have good products. So, it could pull back but I see recovery if that happens. a pullback happening would probably take some bad press or fake news.
Inovio: $17 to $21 short (Overvalued + Small Dip)Please remember everything I say is on the basis of opinion and not meant to be face value. That being said, Inovio pharmaceuticals is overvalued given its hugely bullish increase, but has one of the biggest growth potentials for 1 to 3 weeks. Again, this is likely a quick sale stock rather then long term. A primary reason for the quick sale would be the fact that Inovio is working on a Coronavirus related vaccine. Given this, you could expect a potentially sudden increase in price, but soon just as sudden or as deep of a decrease. That is why it would be good to invest in the dip (which slightly just passed), but still hold this for a few weeks, then reinvest much later on, when news is about to come related to clinical trials and such. That way you put less risk on a hugely bearish decrease. The post-market is already negative, but I think next few weeks Inovio still has even some growth potential in its continued bull run. It does look like this small biotech company should be on the watchlist for many investors. Though I recommend a swing strategy, this doesn't necessarily condone doing a long hold instead, but it is less risk and has better potential (in my opinion).
INO Cup and handleExpecting to hit 16.82, come back down to touch at 11.8 before completing the cup and handle breakout.
$INO Jumps Higher on Cramerica AttentionINO squeezes into key resistance following a Jim Cramer shout-out on CNBC. If I was long the stock from $2 (which I am not), I would be loving the sound of the cash register at this point.
Long INO; Inovio Pharmaceuticals to the MoonNOTE:
✨ We provide charts every day ✨
Like and Follow to help us grow family! 🎉
SUMMARY:
We recently got a clear long entry on Inovio Pharmaceuticals (INO) on the four hour. Will this COVID play make big money?
---
STRATEGY USED:
Momentum Mover
Trend Confirmation = Fractal Trend
Entry Signal = Breakaway Scalper
Exit Signal = Breakaway Scalper OR Orderblock Mapping
---
DESCRIPTION:
1. Fractal Trend is showing an uptrend (Green background color) on INO.
2. Breakaway Scalper recently confirmed a long entry (Green bar color).
3. We are using the Breakaway Scalper's built in automated trailing stop to lock in profits and limit risk.
4. This trade is best entered immediately, for example via extended hours trading. However, if taking it in the morning, double check to make sure the trade is still valid.
4. Looking at the previous highs at R1 for potential resistance if price moves up.
5. Looking at the Bullish order block and general range at S1 for support if we go lower.
$INO - just LOOK AT THESE PATTERNSBill Gates invested in this company, PR is good every week. Volume is going to swing up I believe with the fast advancements they are doing and the increasing publicity. FA + TA confluence here is a beautiful thing, and it's beneficial for society. What more could you want in a trade and long term investment? Fib + EW + trend... cheers!
INO, BAT PATTERN, possible breakout and retest, 400% possibleI AM NOT A FINANCIAL ADVISER, DO YOUR OWN RESEARCH!
$ino possible pennant pattern. Going to move up or down soon. i see a pennant pattern. what do you see?
$COCP Short Articles Published Drowned out by FACTS PPS Rises03-06-2020, 3.5 Million Share Institutional Buy-In tells only a snippet of the overall story with this dream stock.
sec.report
To get the real grasp of what we have here, look to my previous post and take in this analogy as deeply as possible:
In the Coronavirus Market: $COCP is to Treatment what $IBIO is to Vaccines or what $OPK is to Testing.
$COCP has completed all the financing and funding needed with two public offerings recently and are now aggressively pursing the development of Novel Anitiviral Compounds for treatment of any Corona infections including COVID-19
They have exclusive patent rights to the treatment and are in the process of advancing it quickly through a preclinical trial program.
Shorts will continue to write articles to downplay these facts as much as possible because the stock has a HUGE short position
$COCP Clears the Runway for a $10+ move In the coming daysBOTHELL, WA,, March 06, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage
Biotechnology company discovering and developing novel antiviral therapeutics, today announced it has initiated its Coronavirus program.
finance.yahoo.com
“Following our acquisition of patent rights and know-how from KSURF
and our recently completed financing,
we are aggressively pursuing the development of novel antiviral compounds for the treatment of Coronavirus infections using our established proprietary drug discovery platform.
Given the global threat of COVID1-9, our primary goal is to advance
our Coronavirus program into preclinical development.
We will seek opportunities for collaborations as we advance our programs,” stated
Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal.
Cocrystal recently entered into a license agreement with KSURF
to further develop certain proprietary broad-spectrum antiviral compounds for humans to treat Norovirus and Coronavirus infections.
Cocrystal intends to pursue research and development of theses
antiviral compounds, including preclinical and clinical development.
This license advances the Company's antiviral programs significantly by providing potent compounds for further development.
For additional information about the Company’s development pipeline, please visit www.cocrystalpharma.com.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.
Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that it has entered into a license agreement with Kansas State University Research Foundation (“KSURF”) to further develop certain proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections.
Under the terms of the agreement, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans covered by KSURF’s patents. Cocrystal intends to pursue research and development of theses antiviral compounds, including preclinical and clinical development. This license advances the Company's antiviral programs significantly by providing potent compounds for further development.
“We are incredibly pleased to contract with the Kansas State University Research Foundation as we seek to develop safe and effective antiviral therapies for these viruses. This license agreement opens several development opportunities for us to expand the broad utility of our platform to address significant viruses for which there are unmet medical needs, particularly the COVID-19 coronavirus and norovirus,” commented Dr. Sam Lee, President of Cocrystal. “There is an urgent demand to address the public health threat that the coronavirus continues to present, and we believe that our proprietary drug discovery platform has the capability to do just that. We intend to seek opportunities for collaborations as we advance these programs.”
Cocrystal’s technology generates a 3-D structure of inhibitor complexes at near-atomic resolution providing the Company with the ability to identify novel binding sites, which allows for a rapid turnaround of structural information through highly automated X-ray data processing and refinement. By utilizing this technology, Cocrystal is able to develop compounds that specifically target enzymes that are important to viral replication. The Company is currently leveraging its unique structure-based technologies to develop antiviral drugs for hepatitis C, influenza and norovirus.
INO: lost opportunity, not the first and not the last one.Crazy bull run from INO, which was missed and partially screwed up.. I realized some profit, but well below my target.
Entered the market at 4.28 and jumped out at 5.13, while my target was around 8.45..
I should have followed the initial plan, i should't have jumped out, i could realize more.. now i would do this, i would do that, blablabla...
It's easy to speak and difficult to act.
This is one of the lessons that I got during my trading career and which I want to share: "shoulda, coulda, woulda" obviously doesn't work.
I believe there are still plenty of them waiting out there, so everyday is a lost opportunity, but at the same it's just another one to focus on.
Move on and concentrate on what you have instead of what you don't.
//
I want to thank you guys (and of course my future wife) for all of the support you gave me during this 2 month, it helps me to improve and motivates me to do what i am doing here.
$ADGS Potential R/M with new Officer listed LF, PPS Target $50+$ADGS New CEO listed and $200,000 in Taxes paid to get the company up to date on filings. Usually when this happens there's a good reason for it such as a potential R/M and a big one. So far there's been several Xu connections; One to a medical company that is dealing with the Corona-virus, a large Burger Franchise overseas and a large tech company. There is no concrete connection yet, but we have loaded and will wait for more filings. Personal target based on the S/S $50+
